SCHEMBL738238

SCHEMBL738238

CC(C)(C)[C@H](N)C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2032829 1.00
SCHEMBL1534982 1.00
Hydrochloric Acid SCHEMBL27147331 0.97 DPP4 (0.43)
Hydrochloric Acid SCHEMBL1217456 0.97 DPP4 (0.43)
Hydrochloric Acid SCHEMBL14152640 0.97 DPP4 (0.43)
Trifluoroacetic Acid SCHEMBL4683202 0.85 ALDH1A1 (0.38)
Trifluoroacetic Acid SCHEMBL30154872 0.85 ALDH1A1 (0.38)
SCHEMBL29617079 0.84
SCHEMBL21955854 0.79
SCHEMBL7335094 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 WO disclosed
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2026-03-26 US disclosed
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF ALPHA 9 ONCOLOGY INC (CA) 2026-03-19 US disclosed
US-20250381187-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2025-12-18 US disclosed
US-12440491-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2025-10-14 US disclosed
WO-2025087375-A1 NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE AGONIST AND USE THEREOF 南京瑞初医药有限公司 2025-05-01 WO disclosed
EP-3564214-B1 INDAZOLE DERIVATIVES AS MODULATORS OF THE CANNABINOID SYSTEM UNIV DEGLI STUDI G DANNUNZIO CHIETI PESCARA (IT) 2024-07-03 EP disclosed
US-12018093-B2 Hemiasterlin derivatives and antibody-drug conjugates including same Sumitomo Pharma Co., Ltd. (JP) 2024-06-25 US disclosed
US-20240050430-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. 2024-02-15 US disclosed
US-11795195-B2 Antibody-drug conjugates including hemiasterlin derivative Sumitomo Pharma Co., Ltd. (JP) 2023-10-24 US disclosed
EP-1089963-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE SMITHKLINE BEECHAM PLC (GB) 2001-04-11 EP disclosed
US-6127427-A ACTIVE HYDROXAMIC ACIDS INVOLVED IN TISSUE DEGRADTION AND ALSO ARE INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR FROM CELLS; RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, VISION DEFECTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-10-03 US disclosed
WO-1999067201-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE SMITHKLINE BEECHAM PLC (GB) 1999-12-29 WO disclosed
EP-0712390-B1 SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS CELLTECH THERAPEUTICS LTD (GB) 1998-12-09 EP disclosed
EP-0873304-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-10-28 EP disclosed
US-5827890-A ANGIOGENESIS INHIBITORS CELLTECH THERAPEUTICS LTD. (GB) 1998-10-27 US disclosed
US-5710322-A Optically active iminocarboxylic acid derivatives HOFFMANN-LA ROCHE INC. (US) 1998-01-20 US disclosed
WO-1997019053-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1997-05-29 WO disclosed
EP-0712390-A1 SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 1996-05-22 EP disclosed
WO-1995004033-A1 SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS CELLTECH LIMITED (GB) 1995-02-09 WO disclosed